Lurasidone and cariprazine are the newer antipsychotics that have substantially changed the bipolar treatment landscape — particularly for patients who can't accept the metabolic burden of quetiapine or olanzapine. Both have bipolar depression indications and substantially cleaner metabolic profiles than the older atypicals. Both have specific quirks worth knowing.
- Class
- Second-generation antipsychotics (used as mood stabilizers)
- Mechanism
- Lurasidone: D2 antagonist, 5-HT2A antagonist, 5-HT7 antagonist, 5-HT1A partial agonist. Cariprazine: D3-preferring D2/D3 partial agonist, 5-HT1A partial agonist.
- Typical dose
- Lurasidone 20-120 mg/day with food. Cariprazine 1.5-6 mg/day.
- Half-life
- Lurasidone ~18 hours; cariprazine very long (~2-4 days parent, active metabolite ~1-3 weeks)
- FDA indications
- Lurasidone: bipolar depression, schizophrenia. Cariprazine: bipolar mania, bipolar depression, schizophrenia, MDD adjunct.
- Key adverse effects
- Akathisia (both), parkinsonism, somnolence/insomnia, nausea, modest weight gain (less than olanzapine/quetiapine)
Favorable metabolic profile relative to quetiapine/olanzapine — preferred when metabolic burden is concern. Lurasidone requires food ≥350 kcal for absorption. Cariprazine's long half-life makes effects (including side effects) emerge and resolve slowly.
Lurasidone — Latuda — is approved for bipolar depression and schizophrenia. The metabolic profile is among the best in the class: minimal weight gain, minimal lipid effects, minimal glucose dysregulation. For the patient with bipolar depression and metabolic risk, lurasidone is often the right answer where quetiapine would have been historically.
The food requirement is the catch. Lurasidone absorption is markedly reduced without food — bioavailability drops roughly in half if taken on an empty stomach. The FDA label specifies a meal of at least 350 calories. This isn't a comfort recommendation; it's an efficacy requirement. The patient who skips breakfast and takes lurasidone in the morning may not be getting therapeutic effect at all. Counsel this explicitly.
Lurasidone and cariprazine are second/third-generation antipsychotics with specific evidence for bipolar depression and favorable metabolic profiles.
Mechanism note: Lurasidone and cariprazine are the metabolically-favorable choices for bipolar depression; the trade-off is akathisia risk and, for lurasidone, the food requirement.
Akathisia is the clinical tolerability constraint. Lurasidone produces meaningful akathisia in a substantial subset of patients — sometimes severe enough to discontinue. The patient who reports new inner restlessness, inability to sit still, or worsening anxiety on lurasidone may be experiencing akathisia, not the original mood disorder worsening. Treatment: propranolol, dose reduction, or switch.
Cariprazine — Vraylar — is approved for schizophrenia, bipolar mania, bipolar depression, and MDD adjunct. The breadth is unusual. The mechanism is D3-preferring partial agonism — D3 receptors are concentrated in limbic regions, which is the theoretical rationale for cognitive and negative-symptom benefits. The half-life is very long — parent drug 2-4 days, active metabolite 1-3 weeks. Slow on, slow off. Missed doses are buffered; switching to or from cariprazine takes weeks.
Both agents have replaced quetiapine in many bipolar depression cases. The choice between them often comes down to side effect tolerability — lurasidone's akathisia vs cariprazine's slower kinetics and longer washout. Cost has historically been higher than generics; that's narrowed with time but remains a consideration.
- Cost
- Lurasidone generic ~$30-60/month (recent). Brand Latuda ~$1,400/month. Cariprazine (Vraylar) brand-only ~$1,500/month.
- Generic status
- Lurasidone generic since 2023. Cariprazine no generic.
- Formulary typical
- Lurasidone generic: Tier 2. Cariprazine: specialty tier with PA universal.
- Access friction
- For cariprazine, PA documenting prior failed trials. Co-pay cards from Allergan/AbbVie reduce commercial OOB. Lurasidone food requirement is daily friction.
Prescriber tip: Lurasidone now generic — substantially more accessible than 2 years ago. Cariprazine PAs often go through after documenting 2 failed prior agents. Vraylar Savings Card for commercial patients.